This phase I trial is trying to determine whether a new oral cancer drug is safe for patients with neuroblastoma that has not responded or has come back using previous treatment.
This trial is treating patients with neuroblastoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
This trial contains a dose escalation and dose expansion phase. Across both the dose escalation and expansion phase, patients will be randomised to receive oral LY3295668 Erbumine alone or in combination with intravenous topotecan and cyclophosphamide.
Recruiting Hospitals Read More